Antibody conjugates for treatment of neoplastic disease
CA 2079902 C · Owner: Rosenblum, Michael G. · Inventors: Rosenblum, Michael G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Immunoconjugates of an antibody to a 240 kD melanoma tumor associated antigen were prepared. Cytotoxic immunocon-, jugates such as ZME-018 antibody conjugate are useful for treating proliferative cell diseases such as melanoma as well as other tumors which bear the ZME-018 antigen. Detectably labeled compositions for diagnosis of such diseases are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 19, 1991 and granted August 28, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 19, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 19, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.